Drug Profile
Research programme: CD74-targeted cancer therapeutics - Immunomedics
Alternative Names: 20-(74)-(74); 20-74-74; 74-(20)-(20); 74-20-20; Anti-CD74 antibodies - Immunomedics; CD74-RNaseLatest Information Update: 27 Oct 2020
Price :
$50
*
At a glance
- Originator IBC Pharmaceuticals; Immunomedics
- Developer Immunomedics
- Class Antibodies; Bispecific antibodies
- Mechanism of Action Invariant chain inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer